Table 1.
Distribution of clinical data of the samples in the two subgroups.
| Characteristic | C1 (n = 421) | C2 (n = 242) | |
|---|---|---|---|
| Status | Alive | 338 | 78 |
| Dead | 83 | 164 | |
| Age | Mean (SD) | 42 (13.5) | 55.1 (14.4) |
| Median[MIN,MAX] | 39 [14,87] | 57 [21,89] | |
| Gender | Female | 182 | 100 |
| Male | 239 | 142 | |
| Race | American Indian | 1 | 0 |
| Asian | 6 | 7 | |
| Black | 16 | 15 | |
| White | 389 | 218 | |
| Grade* | Discrepancy | 1 | 0 |
| G2 | 236 | 12 | |
| G3 | 179 | 82 | |
| New tumour event type | Progression | 2 | 62 |
| Recurrence | – | 16 | |
| Radiation therapy* | Non-radiation | 109 | 11 |
| Radiation | 104 | 39 | |
| History of neoadjuvant therapy | Yes | 3 | |
| No | 418 | 242 | |
| Therapy type* | Ancillary : Chemotherapy:Targeted Molecular Therapy | 1 | |
| Chemotherapy | 175 | 107 | |
| Chemotherapy: | 5 | 2 | |
| Chemotherapy : Targeted Molecular Therapy | 1 | – | |
| Chemotherapy : Hormone Therapy | 1 | 15 | |
| Chemotherapy : Hormone Therapy : Immunotherapy: | 1 | – | |
| Chemotherapy : Hormone Therapy : Other (specify in notes) | 3 | – | |
| Chemotherapy : Immunotherapy | 8 | 5 | |
| Chemotherapy : Other (specify in notes) | 3 | 1 | |
| Chemotherapy : Targeted Molecular Therapy | 17 | 36 | |
| Immunotherapy | 2 | – | |
| Chemotherapy : Hormone Therapy : Other (specify in notes):Targeted Molecular Therapy | – | 1 | |
| Chemotherapy : Hormone Therapy : Targeted Molecular therapy | – | 1 | |
| Chemotherapy : Immunotherapy:Targeted Molecular Therapy | – | 2 | |
| Hormone Therapy | – | 6 | |
| Hormone Therapy : Targeted Molecular Therapy | – | 1 |
*p < 0.05.